CytomX Therapeutics Stock (US23284F1057): Analyst Rating Change from HC Wainwright on 04/ 25/ 2026

HC Wainwright raised its price target for CytomX Therapeutics (CTMX) to $15 from $9 on April 25, 2026, citing positive clinical data from the Probody platform. The stock rose 2.8% on April 28, 2026, on the NASDAQ.

HC Wainwright raised its price target for CytomX Therapeutics stock to $15 from $9 on April 25, 2026, according to a research note from the firm. The upgrade reflects optimism around the company's Probody drug conjugate platform following recent clinical updates.

As of: May 01, 2026

By the AD HOC NEWS Editorial Team – Equity Coverage.

At a Glance

• Name: CTMX
• ISIN: US23284F1057
• Sector/Industry: Biotechnology
• Headquarters/Country: South San Francisco, United States
• Primary Exchange: NASDAQ
• Trading Currency: USD

How CytomX Therapeutics Makes Money: The Core Business Model

CytomX Therapeutics develops conditionally activated oncology therapeutics using its Probody therapeutic platform. The platform masks protease-cleavable antibodies that activate selectively in the tumor microenvironment, aiming to improve safety and efficacy profiles.

The company advances wholly owned and partnered programs across multiple modalities, including Probody drug conjugates and bispecific antibodies. Revenue stems from collaboration agreements, milestone payments, and research funding from partners like Amgen, Bristol Myers Squibb, and Regeneron.

For the quarter ended December 31, 2025, CytomX reported collaboration revenue of $14.2 million, according to its 10-K filing dated February 27, 2026.

CytomX Therapeutics's Key Revenue and Product Drivers

CX-2051, a Probody drug conjugate targeting CD166, showed promising early data in a phase 1 trial, contributing to analyst optimism. The program targets solid tumors and is wholly owned by CytomX.

CX-801, an IL-12 Probody cytokine, advanced in clinical development for advanced solid tumors. Partnership revenue from existing deals provided $14.2 million in Q4 2025 collaboration revenue, per the 10-K dated February 27, 2026.

Guidance for 2026 projects collaboration revenue between $50 million and $60 million, according to the company's press release dated February 27, 2026.

Industry Trends and Competitive Landscape

The antibody-drug conjugate (ADC) market is projected to reach $26 billion by 2030, driven by demand for targeted therapies in oncology, according to EvaluatePharma, 2025. CytomX differentiates with its tumor-selective activation.

Competitors include Seagen (acquired by Pfizer), ImmunoGen (acquired by AbbVie), and Daiichi Sankyo, all advancing ADCs with different linker technologies. CytomX's Probody platform offers a unique masked approach to reduce off-tumor toxicity.

Recent FDA approvals of ADCs like Enhertu and Trodelvy highlight the segment's momentum, with over 10 ADCs approved in the US as of 2025.

Why CytomX Therapeutics Matters to US Investors

CytomX Therapeutics trades on the NASDAQ under ticker CTMX in USD, providing direct access for US investors. The company files with the SEC, ensuring transparency through 10-K and 10-Q reports.

With headquarters in South San Francisco, California, CytomX focuses on US clinical trials and FDA interactions. Its pipeline targets high-prevalence US cancers like pancreatic and prostate.

The stock traded at $1.45 on the NASDAQ on April 28, 2026, at 4:00 PM ET, up 2.8% vs. previous close on April 25, 2026, according to NASDAQ.com data.

Which Investor Profile Fits CytomX Therapeutics – and Which Does Not?

Biotech investors tolerant of clinical-stage risks may track CytomX for its innovative Probody platform and partnerships with major pharma. The focus on next-gen ADCs aligns with sector growth.

Conservative profiles seeking stable dividends or mature revenue streams find limited fit, given CytomX's pre-commercial status and reliance on milestones. Large-cap dividend strategies diverge from this micro-cap biotech play.

Active traders monitor catalysts like data readouts, while long-term growth seekers eye platform validation through partner progress.

What Analysts Are Saying About CytomX Therapeutics Stock

HC Wainwright raised its price target to $15 from $9 on April 25, 2026, maintaining Buy rating, per their research note. The firm highlighted CX-2051 phase 1 data showing 40% disease control rate.

Other analysts include Piper Sandler with Overweight at $5 (March 15, 2026) and Wedbush with Outperform at $13 (April 10, 2026), reflecting varied targets amid pipeline momentum.

Risks and Open Questions for CytomX Therapeutics

Clinical trial risks persist, with CX-2051 phase 1 expansion data pending in H2 2026. Historical biotech attrition rates exceed 90% for phase 1 to approval.

Funding needs remain, with $144 million cash as of December 31, 2025, per 10-K dated February 27, 2026, supporting operations into 2027 but vulnerable to delays.

Partner dependency introduces execution risk, as milestone timing depends on Amgen and BMS progress in their respective programs.

Key Events and Outlook for Investors

CytomX plans Q1 2026 earnings release on May 15, 2026, pre-market, with conference call at 8:00 AM ET, per IR calendar. CX-2051 data updates expected mid-2026.

Potential milestones from partner programs could trigger payments within 2026 guidance range of $50-60 million collaboration revenue.

What to Watch Next

• May 15, 2026: Q1 2026 earnings and call
• H2 2026: CX-2051 phase 1 data readout

Conclusion

The HC Wainwright price target increase to $15 on April 25, 2026, underscores pipeline potential amid Probody platform advances. US investors benefit from NASDAQ listing and SEC oversight. Upcoming Q1 earnings on May 15, 2026, offer further visibility into 2026 guidance execution.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.